

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Project Agreements with the University of Michigan

Action Requested: Authorization to enter into or amend Agreements

Preamble:

Statutory conflicts of interest situations were identified by the Office of Research and Sponsored Projects while reviewing Proposal Approval Forms that then triggered a review by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved at time of award.

These proposed project (e.g., research, sponsored activity, and/or subcontract) agreements (“Agreement”) and/or amendments to Agreements (“Amendments”) fall under the State of Michigan Conflict of Interest Statute because University of Michigan (“University”) employees have activities, relationships, or interests in the companies as described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents (“Regents”) of the University and approved in advance by a 2/3 vote.

Agreement Terms:

The terms of the Agreements and/or Amendments conform to University policy. The funding support will not exceed the amount reported in Attachment A for each Agreement and/or Amendment. Since projects are often amended, these Agreements and/or Amendments include provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreements and/or Amendments will provide support of investigator’s effort to use their expertise and University laboratories, as well as other University resources, to execute the projects as reported in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreements and Amendments were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into or amending the Agreements referenced in Attachment A.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Rebecca Cunningham', with a stylized, cursive script.

Rebecca Cunningham
Vice President for Research

February 2022

Attachment A

Project #1

Research Agreement between the University and Eli Lilly and Company Reviewed by the Medical School Conflict of Interest Board	
<u>Project Information</u>	
Title: Rapid and Predictive Computational Catalysis Screening	U-M Project ID: 22-PAF03350
Direct Sponsor: Eli Lilly and Company	
Principal Investigator/Department: Paul Zimmerman, Chemistry	
Project Duration: Two (2) Years	Funding Support: \$264,000
Purpose: The purpose of this project is to develop a hybrid computational approach which uses fast semiempirical methods for pre-screening and quantum mechanical (QM) methods for accurate optimization and build an automated tool for rapid catalyst screening and deliver optimized designs directly to experimental scientists.	
<p><u>University Employee; University Title; Relationship with Eli Lilly and Company</u></p> <ul style="list-style-type: none">• Marschall Runge; Executive Vice President for Medical Affairs, Dean of the Medical School; Board of Directors Member	

Project #2

STTR Phase I Subcontract Agreement between the University and GeneToBe, LLC Reviewed by the Medical School Conflict of Interest Board	
<u>Project Information</u>	
Title: Development of miCas9 mediated gene editing therapies for cystic fibrosis - STTR Phase I Resub	U-M Project ID: 22-PAF03462
Direct Sponsor: GeneToBe, LLC	Prime Sponsor: National Institutes of Health
Principal Investigator/Department: Jie Xu, Internal Medicine-Cardiology	
Project Duration: One (1) Year	Funding Support: \$100,000
Purpose: The purpose of this project is to develop a gene editing therapy strategy for cystic fibrosis.	
<p><u>University Employee; University Title; Relationship with GeneToBe, LLC</u></p> <ul style="list-style-type: none">• Yuqing Chen; Professor, Cardiovascular Medicine; Partial Owner• Jie Xu; Research Associate Professor, Internal Medicine-Cardiology; Partial Owner	

Project #3**STTR Phase I Subcontract Agreement between the University and GeneToBe, LLC
Reviewed by the Medical School Conflict of Interest Board****Project Information****Title:** Gene-editing therapy to treat vision loss in Usher Syndrome type 3 - STTR Phase I Resub**U-M Project ID:** 22-PAF03482**Direct Sponsor:** GeneToBe, LLC**Prime Sponsor:** National Institutes of Health**Principal Investigator/Department:** Dongshan Yang, Internal Medicine-Cardiology**Project Duration:** One (1) Year**Funding Support:** \$90,000**Purpose:** The purpose of this project is to test the feasibility and safety of miCas9 mediated gene editing therapy for USH3A using cultured rabbit fibroblasts and retina explants isolated from the USH3A KI rabbit model established.**University Employee; University Title; Relationship with GeneToBe, LLC**

- Yuqing Chen; Professor, Cardiovascular Medicine; Partial Owner
- Jie Xu; Research Associate Professor, Internal Medicine-Cardiology; Partial Owner

Project #4**Second Amendment to a Subcontract Agreement between the University and May Mobility, Inc.
Reviewed by the UMOR Conflict of Interest Review Committee****Project Information****Title:** Inclusive Design Challenge-Phase I - Additional Task 2**U-M Project ID:** 22-PAF04323**Direct Sponsor:** May Mobility, Inc.**Prime Sponsor:** Department of Transportation**Principal Investigator/Department:** Kathleen Klinich, University of Michigan Transportation Research Institute-Biosciences Group (UMTRI)**Agreement Initiated:** February 1, 2021**Current Project Duration:** Seventeen (17) Months
Additional Time: N/A**Current Funding Support:** \$123,744
Additional Funding Support: \$50,000**Purpose:** The purpose of this amendment is to add additional funds so that Dr. Klinich may perform additional tasks related to wheelchair anchor design, construction, and testing.**University Employee; University Title; Relationship with May Mobility, Inc.**

- Edwin Olson; Professor, Electrical Engineering and Computer Science; Partial Owner

Project #5

Research Agreement between the University and Phenomics Health Inc. Reviewed by the Medical School Conflict of Interest Board	
<u>Project Information</u>	
Title: Longitudinal Patient-Specific Drug Response Prediction to Validate and Extend Phenomics Health Pharmacogenomic Tests Phase 1	U-M Project ID: 22-PAF03766
Direct Sponsor: Phenomics Health Inc.	
Principal Investigator/Department: Brian Athey, Computational Medicine and Bioinformatics	
Project Duration: One (1) Year	Funding Support: \$574,886
Purpose: The purpose of this project is to lay the groundwork and build the necessary research infrastructure to create, demonstrate and evaluate a new first-generation and then second-generation neuropsychiatric pharmacogenomics (PGx) diagnostic assay for patients suffering from Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD), Generalize Anxiety Disorder (GAD), and Substance Use Disorder (SUD).	
<u>University Employee; University Title; Relationship with Phenomics Health Inc.</u> <ul style="list-style-type: none">• Brian Athey; Professor, Computational Medicine and Bioinformatics; Partial Owner• Gilbert Omenn; Professor, Computational Medicine and Bioinformatics; Board of Directors Member	

Project #6

SBIR Phase II Subcontract Agreement between the University and Theia Scientific, LLC Reviewed by the UMOR Conflict of Interest Review Committee	
<u>Project Information</u>	
Title: An Open Analysis Platform with In-Situ Machine Vision for Electron Microscopy	U-M Project ID: 22-PAF02901
Direct Sponsor: Theia Scientific, LLC	Prime Sponsor: Department of Energy
Principal Investigator/Department: Kevin Field, Nuclear Engineering and Radiological Sciences	
Project Duration: Two (2) Years	Funding Support: \$330,000
Purpose: The purpose of this project is to expand the number of machine learning models hosted on learning platforms.	
<u>University Employee; University Title; Relationship with Theia Scientific, LLC</u> <ul style="list-style-type: none">• Kevin Field; Professor, Nuclear Engineering and Radiological Sciences; Partial Owner	

Project #7**STTR Phase I Subcontract Agreement between the University and Tulip Make Me Move Desk, LLC
Reviewed by the Medical School Conflict of Interest Board****Project Information****Title:** STTR Ph I A0 Bohnen: Development of a Multifunctional Rehabilitation Standing and Stepping Device for persons with Parkinson's disease**U-M Project ID:** 22-PAF03894**Direct Sponsor:** Tulip Make Me Move Desk, LLC**Prime Sponsor:** National Institutes of Health**Principal Investigator/Department:** Nicolaas Bohnen, Radiology**Project Duration:** One (1) Year**Funding Support:** \$150,500

Purpose: The purpose of this project is to: (i) develop a next-generation Multifunctional Rehabilitation Standing & Stepping Device (MRSSD) multidirectional and variable range and intensity mobility and cognitive-motor rehabilitation therapy device, (ii) collect user acceptance and in-lab feasibility of repeated use data, and (iii) conduct a pilot controlled clinical trial to generate data to power a large scale clinical trial in Phase II.

University Employee; University Title; Relationship with Tulip Make Me Move Desk, LLC

- Nicolaas Bohnen; Professor, Radiology; Partial Owner